A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

NCT06693843 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

220

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity, Overweight, or Chronic Weight Management

Interventions

DRUG: Aleniglipron or Placebo
DRUG: Aleniglipron or Placebo
DRUG: Aleniglipron or Placebo
DRUG: Aleniglipron
DRUG: Aleniglipron
DRUG: Aleniglipron
DRUG: Aleniglipron

Sponsor

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics